initial public offerings (IPOs) trading on American exchanges

Friday, July 16, 2021

Erasca (ERAS) began trading on the Nasdaq on Fri 16 July 21

Erasca priced upsized 18.8 mln share IPO at $16/share, at the high end of the $14-16 expected range

Erasca is a precision oncology company working to develop new anti-cancer drugs. The company is following multiple strategies in its research, to discover, develop, and eventually commercialize new medication therapies for RAS and MPAK pathway cancers. Erasca has a pipeline of 9 separate drug candidates.

The lead candidate in the pipeline, EARS-007, is being studied as a treatment for various solid and liquid tumors, as well as non-small cell lung cancer. The drug has four separate tracks under investigation, with one (the tissue agnostic RAS/MPAK altered solid tumor track) entering a Phase 1b/2 clinical trial, the HERKULES-1 trial. The other indications for this drug candidate are the subjects of HERKULES 2 through 4, which are planned to start later this year.

No comments:

Post a Comment